Skip NavigationSkip to Content
Return Return to Search Results

The mechanism responsible for the supraphysiologic gonadotropin surge in females treated with gonadotropin-releasing hormone (GnRH) agonist and primed with GnRH antagonist

  1. Author:
    Taylor, J. E.
    Miller, B. T.
    Gray, K. D.
    Scott, R. T.
    Catherino, W. H.
    Segars, J. H.

  2. Author Address

    [Taylor, Joelle E.; Miller, Bradley T.; Segars, James H.] NIH, Reprod Biol & Med Branch, Bethesda, MD 20892 USA. [Taylor, Joelle E.] Wake Forest Univ, Bowman Gray Sch Med, Dept Obstet & Gynecol, Winston Salem, NC 27103 USA. [Miller, Bradley T.; Catherino, William H.; Segars, James H.] Uniformed Serv Univ Hlth Sci, Dept Obstet & Gynecol, Bethesda, MD 20814 USA. [Gray, Karen D.] NCI, NIH, Frederick, MD 21701 USA. [Scott, Richard T., Jr.] Reprod Med Associates New Jersey, Morristown, NJ USA.;Segars, JH, NICHD, Program Reprod & Adult Endocrinol, Bldg CRC,Room 1E3140,10 Ctr Dr, Bethesda, MD 20814 USA.;segarsj@mail.nih.gov
    1. Year: 2010
    2. Date: Mar
  2. Journal: Fertility and Sterility
    1. 93
    2. 5
    3. Pages: 1668-1675
  4. Type of Article: Article
  5. ISSN: 0015-0282
  1. Abstract:

    Objective: To elucidate the physiologic mechanism responsible for the supraphysiologic gonadotropin release from the pituitary induced by gonadotropin-releasing hormone (GnRH) agonist in female rats primed with GnRH antagonist. Design: Controlled experimental intervention. Setting: Government research facility. Animal(s): Forty 8-week-old Sprague-Dawley rats. Intervention(s): Forty oophorectomized rats were randomized into four treatment groups of 10: group A. control vehicles; group B. GnRH agonist (leuprolide acetate; 1.7 mu g/kg twice a day) on day 4; group C. GnRH antagonist (Nal-Lys; 3 mg/kg each day) days 1 to 4; or group D, GnRH antagonist (Nal-Lys; 3 mg/kg each day) days 1 to 4 plus GnRH agonist (1.7 mu g/kg twice a day) on day 4. Main Outcome Measure(s): Immunohistochemical methods, Northern and in situ hybridization to quantitate pituitary follicle-stimulating hormone beta (FSH-beta), luteinizing hormone beta (LH-beta), and GnRH receptor (GnRH-R) messenger RNA (mRNA), and receptor protein levels in all treatment groups. Result(s): Treatment with GnRH antagonist was associated with increased storage of gonadotropin in the pituitary for FSH-beta and LH-beta, but mRNA levels were unchanged. The GnRH-R mRNA decreased after GnRH-agonist treatment but remained stable in the GnRH-antagonist treatment groups. Levels of GnRH-R were decreased after GnRH-antagonist treatment. Conclusion(s): These data indicate that the in vivo mechanism responsible for the exaggerated release of gonadotropins in rats primed with GnRH antagonist and treated with GnRH agonist was an increase in releasable gonadotropin pools coupled with a reduction in GnRH-R, but receptor function was preserved. (Fertil Steril (R) 2010;93:1668-75. (C)2010 by American Society for Reproductive Medicine.)

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.fertnstert.2008.12.047
  3. View record in Web of Science®
  4. WOS: 000276038700037

Library Notes

  1. Fiscal Year: FY2009-2010
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel